A Double-Blind Trial of Intramuscular Stanozolol in the Prevention of Postoperative Deep Vein Thrombosis Following Elective Abdominal Surgery

Summary

Fibrinolytic shutdown may be important in the development of postoperative deep vein thrombosis (DVT). We have previously shown that stanozolol 50 mg, given intramuscularly 24 hr before surgery, prevents the decrease in plasminogen activator activity (PA) seen on the first postoperative day in patients at high risk of DVT. To investigate the role of fibrinolytic shutdown in causation of DVT, sixty patients were randomised in a double-blind controlled trial to receive stanozolol or placebo intramuscularly, and DVT was detected by leg scanning and confirmed by venography. Scan positive DVT occurred in IT of 31 placebo patients (35%) and 12 of 29 who received stanozolol (41%). A significant decrease in PA was confirmed in the placebo group, while stanozolol caused a significant increase in PA on the first postoperative day. Patients in either group who did not develop DVT showed minimal changes in PA. We conclude that prevention of fibrinolytic shutdown by this regimen of stanozolol does not prevent postoperative DVT, and that further studies are required to clarify the relationships of postoperative fibrinolysis and DVT.

Key Words

Fibrinolysis - Plasminogen activator - Deep vein thrombosis

• References

• 1 Morris GK. Prevention of venous thromboembolism. Lancet 1980; 2: 572-574
• 2 Negus D, Pinto DJ, Le Quesne LP, Brown N, Chapman M. I¹²⁵-labelled fibrinogen in the diagnosis of deep vein thrombosis and its correlation with phlebography. Br J Surg 1968; 55: 835-839
• 3 Mansfield AO. Alteration in fibrinolysis associated with surgery and venous thrombosis. Br J Surg 1972; 59: 754-757
• 4 Gordon-Smith IC, Hickman JA, Le Quesne LP. Postoperative fibrinolytic activity and deep vein thrombosis. Br J Surg 1974; 61: 213-218
• 5 Gallus AS, Hirsh J, Gent M. Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis. Lancet 1973; 2: 805-809
• 6 MacIntyre IM C, Webber RG, Crispin JR, Jones DR B, Wood JK, Allan NC, Prescott RJ, Ruckley CV. Plasma fibrinolysis and postoperative venous thrombosis. Lancet 1976; 2: 38-39
• 7 Allenby F, Jeyasingh K, Calnan J. Ethyloestrenol and postoperative venous thrombosis. Lancet 1974; 2: 38-39
• 8 Fossard DP, Friend JR, Field ES, Corrigan TP, Kakkar VV, Flute PT. Fibrinolytic activity and postoperative deep vein thrombosis. Lancet 1974; 1: 9-11
• 9 Davidson JF, Lochhead GA, McDonald GA, McNicol GP. Fibrinolytic enhancement by stanozolol: a double blind trial. Br J Haematol 1972; 22: 543-559
• 10 Preston FE, Burakowski BK, Porters NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 22: 432-551
• 11 Small M, McArdle BM, Lowe GD O, Forbes CD, Prentice CR M. The effect of intramuscular stanozolol on fibrinolysis and blood lipids. Thromb Res 1982; 28: 27-36
• 12 Blarney SL, McArdle BM, Bums P, Lowe GD O, Forbes CD, Carter DC, Prentice CR M. Prevention of fibrinolytic shutdown after major surgery by intramuscular stanozolol. Thromb Res 1983; 31: 451-459
• 13 Lowe GD O, Osborne DH, McArdle BM, Smith A, Carter DC, Forbes CD, McLaren D, Prentice CR M. Prediction and selective prophylaxis of venous thrombosis in elective gastrointestinal surgery. Lancet 1982; 1: 409-412
• 14 Documenta Geigy. Scientific Tables. 7. Macclesfield: Geigy Pharmaceuticals; 1970. p 712
• 15 Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976; 2: 910-912
• 16 Browse NL, Gray L, Morland M. Changes in the blood fibrinolytic activity after surgery (the effect of deep vein thrombosis and malignant disease). Br J Surg 1977; 64: 23-27